Clinical and genetic characteristics predict outcomes of acute myeloid leukemia patients with FLT3 mutations receiving venetoclax-based therapy.
Journal Information
Full Title: Cancer Med
Abbreviation: Cancer Med
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:
"CONFLICT OF INTEREST STATEMENT The authors declare no competing interests."
Funding Disclosure
Evidence found in paper:
"We sincerely thank all the hospitals involved in this study. This work was supported by Shenzhen Key Medical Discipline Construction Fund (Grant Nos. SZXK008), Special Support Funds of Shenzhen for Introduced High‐Level Medical Team, the National Key Research and Development Program of China (Grant Nos. 2021YFC2500300‐4), Shenzhen Science and Technology Program (Grant Nos. JCYJ20230807115302005)."
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025